The Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug Development

Table 2

Evidence for cytisine and cytisine-based compounds in mouse models of depression.

Study	Compound(s)	CYT-compound dose	Results
Mineur et al. [39]	CYT	1.5 mg/kg^a	Improved FST/TST
Mineur et al. [46]	CYT	1, 1.5 mg/kg	Improved FST/TST
	3-pyr-CYT		Improved FST/TST
	5-Br-CYT		No effect on FST/TST^b
Rollema et al. [52]	VNCL	0.178, 0.56, 1, 1.78, 3.2, 5.6 mg/kg	Improved FST
	VNCL + SERT	0.56, 5.6 mg/kg	Improved FST^c
Kozikowski et al. [58]	SAZ-A	1 mg/kg	Improved FST
Turner et al. [53]	VNCL	0.01, 0.1, 1 mg/kg	No effect on FST
	SAZ-A	1 mg/kg	Improved FST^d
Caldarone et al. [59]	VNCL	0.3, 1, and 3 mg/kg	Improved FST
	SAZ-A	1, 3, and 10 mg/kg	Improved FST

Notes:   ^a0.2, 0.6, 1.0, and 1.5 mg/kg CYT tested.
^bNo CNS penetration.
^cLow dose VNCL (0.56 mg/kg) combined with low dose SERT (1.78 mg/kg) produced no significant effect on FST performance.
^dSAZ-A at doses of 0.05–0.5 mg/kg had no effect on FST performance.
Abbreviations: CYT: cytisine; 3-pyr-CYT: 3-[pyridin-3′-yl]-cytisine; 5-Br-CYT: 5-bromo-cytisine; VNCL: varenicline; SERT: sertraline; SAZ-A: sazetidine-A; FST: forced swim test; TST: tail suspension test.